Best peptides for menopause: which ones work, which are legal, and what to use instead

Which peptides actually work for menopause?

A peptide is simply a short chain of amino acids, the building blocks of protein. The word tells you how a molecule is built. It says nothing about whether it works or whether it is safe.

Insulin is a peptide. So are semaglutide and tirzepatide. So is BPC-157, a lab-made molecule sold online in vials. Here is how the names you keep seeing sort out, strongest evidence first.

• Proven, for weight: GLP-1 drugs. Semaglutide, sold as Wegovy, and tirzepatide, sold as Zepbound, are FDA-approved for chronic weight management in adults with obesity, or overweight plus a weight-related condition. Their large placebo-controlled trials enrolled mostly women in their mid-40s.
• Approved, but for one narrow use: bremelanotide. Sold as Vyleesi and often called PT-141, it is approved for low sexual desire in premenopausal women. Its label says it is not for women after menopause.
• Approved, but not for menopause: tesamorelin. Sold as Egrifta, it is approved only to reduce excess belly fat in adults with HIV who have lipodystrophy, a condition that shifts where the body stores fat.
• Compounded, weak evidence: sermorelin, CJC-1295 and ipamorelin. Wellness clinics sell these growth hormone boosters for energy, sleep and belly fat. None has been tested in a trial of menopausal women.
• Gray market, least evidence: BPC-157 and other research vials. These are sold online as research chemicals. The human data come from a handful of tiny studies with no comparison group.
• Supplement, modest evidence: collagen peptides. This is a powder sold over the counter, not a drug. Skin trials are mixed, and one trial in postmenopausal women found a small bone density gain.

Peptides for menopause weight loss: is a GLP-1 the peptide people mean?

Often it is. Semaglutide and tirzepatide are both peptides, so a weight-loss peptide program can simply be a GLP-1 under another name.

These drugs copy GLP-1, a gut hormone that signals fullness and slows how fast your stomach empties. Tirzepatide also acts on a second gut hormone called GIP. Our GLP-1 explainer covers the mechanism step by step.

The STEP 1 trial randomly assigned 1,961 adults without diabetes to weekly semaglutide or a placebo shot. About three in four were women, and their average age was 46.

After 68 weeks, the semaglutide group had lost 14.9 percent of their body weight on average. The placebo group lost 2.4 percent.

The SURMOUNT-1 trial tested tirzepatide in 2,539 adults, about two in three of them women. At the highest dose, people lost 20.9 percent of their weight over 72 weeks. The placebo group lost 3.1 percent.

Those figures come from separate trials, so they are not a head-to-head contest. Neither trial reported results by menopause stage.

One smaller study looked at hormone therapy alongside semaglutide. It was retrospective, meaning researchers reviewed past patient records rather than running a trial. Of the 106 postmenopausal women in it, 16 used hormone therapy.

In that 2024 study in the journal Menopause, hormone users had lost about 16 percent of their weight at 12 months. Non-users had lost about 12 percent. The design cannot show that the hormones caused the gap.

One label finding matters after 40. In SELECT, the heart outcomes trial on the Wegovy label, hip and pelvis fractures were reported in 1.0 percent of women on Wegovy. That compares with 0.2 percent of women on placebo.

No GLP-1 is FDA-approved for hot flashes. Other peptides sold for fat loss, such as AOD-9604, have no FDA approval for any use. The FDA's compounding review cites possible immune reactions, impurities and limited safety data for AOD-9604.

What about BPC-157, CJC-1295, ipamorelin and other "healing" peptides?

These are the names in wellness videos. They promise faster healing, deeper sleep, a flatter middle or more energy. The human evidence is far thinner than the marketing suggests.

BPC-157

BPC-157 is a lab-made peptide with a large body of animal research on healing. Human research is another story.

A 2025 systematic review of BPC-157 in sports medicine screened 544 articles. It kept 35 animal or lab studies and a single human study, and it found no clinical safety data.

Three small human reports exist in total. All share the same first author and appeared in one alternative-medicine journal.

• Knee pain. A 2021 chart review phoned 16 patients after knee injections and asked whether their pain had eased. There was no comparison group.
• Bladder pain. A 2024 pilot gave one bladder injection to 12 women with interstitial cystitis, a chronic bladder pain condition. It had no control group, and the women rated their own results.
• Safety by vein. A 2025 pilot gave intravenous infusions to two adults and checked their blood tests over a few days.

None of these was randomized, and none involved menopause. The FDA's review says BPC-157 may trigger immune reactions by some routes, with little or no safety information for the routes proposed.

CJC-1295 and ipamorelin

Both are designed to make your pituitary gland, a small gland under the brain, release more growth hormone. Clinics often sell them together.

CJC-1295 was tested in two small placebo-controlled studies of healthy adults aged 21 to 61, published in 2006. They tracked hormone levels for up to seven weeks, not weight, energy or menopause symptoms.

The FDA's review lists serious adverse events with CJC-1295. They include a faster heart rate and a reaction in which blood vessels widen throughout the body.

Ipamorelin's biggest trial was in people recovering from bowel surgery. In that 2014 placebo-controlled trial of 114 patients, it did not speed the return to normal eating more than placebo did.

The FDA notes that a published study linked intravenous ipamorelin to serious adverse events, including a death. It says it lacks enough information on other injected routes.

Two 2026 reviews land in the same place. A sports medicine review found few human studies, most without proper controls. Another review concluded that rigorous human safety data are scarce and serious harm is possible.

Is peptide therapy for menopause legal and safe? What the FDA says

The answer depends on three things: whether the drug is approved, who made it, and what it is sold for. Peptide therapy covers every route, so the answer changes from product to product.

FDA-approved peptides

Wegovy, Zepbound, Vyleesi and Egrifta passed FDA review for safety, effectiveness and quality. Each is legal with a prescription, and each label names the uses that review covered.

Compounded peptides from 503A pharmacies

Compounding means a pharmacy prepares a drug for one patient's prescription. A 503A pharmacy is a state-licensed pharmacy that does this, named after a section of federal drug law.

The FDA says compounded drugs are not FDA-approved. It does not review them for safety, effectiveness or quality before they are sold.

A 503A pharmacy may only use a raw ingredient that meets one of three conditions. It has an official quality standard called a USP or NF monograph, it is part of an FDA-approved drug, or it is on the FDA's 503A bulks list.

While that list is being built, the FDA sorts nominated ingredients into categories. Category 2 means an ingredient may present significant safety risks in compounding. As of the page's April 22, 2026 update, it still includes these ingredients:

• For 503A pharmacies: kisspeptin-10 and ibutamoren. Ibutamoren is a growth hormone booster pill, and it is not a true peptide.
• For 503B outsourcing facilities: GHRP-2, GHRP-6, ipamorelin and ibutamoren. Outsourcing facilities are larger compounders that register with the FDA.

In February 2026, Health Secretary Robert F. Kennedy Jr. said many Category 2 peptides would be reconsidered. In April 2026, 12 of them, including BPC-157, came off Category 2 after the groups that had nominated them withdrew.

The FDA now lists BPC-157, CJC-1295, AOD-9604 and others in a table of withdrawn nominations. Each entry still carries the agency's safety concerns.

Leaving Category 2 is not the same as being cleared. A July 2026 analysis by the law firm McDermott notes that these peptides still meet none of the three 503A conditions until a formal rule adds them.

The July 2026 advisory vote

On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee reviewed seven peptides for the 503A bulks list. FDA staff recommended adding none of them.

The panel voted the other way on six. It backed BPC-157 for ulcerative colitis, a bowel disease. It also backed TB-500, KPV, MOTs-c, Epitalon and Semax. It did not back DSIP, a peptide pitched for sleep.

The vote is advice, not a rule. As of October 19, 2026, no proposed rule adding these peptides has appeared in the Federal Register. None of the uses reviewed was a menopause symptom.

Research use only vials

Gray-market sites sell peptide vials labeled for research purposes or not for human consumption. The FDA has warned companies selling such semaglutide, tirzepatide and retatrutide directly to consumers with dosing instructions.

It urges consumers not to buy these products, which it calls of unknown quality and possibly harmful. That warning names specific weight-loss molecules. For BPC-157 and similar peptides, the FDA's own listed concerns are immune reactions and impurities.

Compounded GLP-1s: where things stand

The FDA declared the tirzepatide shortage over in December 2024. The semaglutide shortage ended on February 21, 2025, which closed the broad copying allowed during shortages.

Licensed 503A pharmacies still compound both drugs for individual prescriptions, under stricter rules. Our compounded GLP-1 guide explains those rules and the providers that follow them.

Sermorelin and growth hormone peptides: energy, sleep, belly fat?

Sermorelin is a short copy of growth hormone-releasing hormone, the brain signal that tells your pituitary gland to release growth hormone. Clinics pitch it for energy, sleep, body shape and skin.

It does have FDA history. Geref, a sermorelin injection from EMD Serono, was approved to treat growth hormone deficiency in children with growth failure. A second form was approved to test how well the pituitary releases growth hormone.

EMD Serono told the FDA in 2008 that it was discontinuing both products, and approval was withdrawn in June 2009. The FDA's notice gives no reason for the discontinuation.

In a 2013 Federal Register notice, the FDA determined that Geref was not withdrawn for reasons of safety or effectiveness.

That history shapes its legal position today. Sermorelin was the active ingredient of an approved drug and is not on Category 2, so licensed 503A pharmacies compound it with a prescription. The compounded product is still not FDA-approved.

The evidence gap is the real problem. No trial has tested sermorelin in menopausal women for energy, sleep or belly fat.

The closest study dates from 1997. Researchers gave a lab version closely related to sermorelin to 10 women and 9 men aged 55 to 71, for 16 weeks after a placebo run-in.

That study found thicker skin in both sexes. Lean body mass, well-being and libido improved in the men only.

So the best direct evidence is one small study, nearly 30 years old, whose benefits favored men.

Tesamorelin and the belly fat pitch

Tesamorelin, sold as Egrifta, is an FDA-approved growth hormone-releasing drug. Its label covers one use: reducing excess belly fat in adults with HIV who have lipodystrophy.

The label also says it is not indicated for weight loss, because its effect on weight is neutral. Using it for menopause belly fat would be off-label, meaning outside the approved use, and no trial has tested that.

What a wellness menu looks like

Some GLP-1 telehealth brands now add sermorelin to their menus. Brello Health lists compounded sermorelin with the tagline "Because being tired all day and wide awake all night is a brutal combo."

Its site makes no specific health claims for sermorelin, and it states that compounded drugs are not FDA-approved. A tagline is not a trial, though. Night sweats often break sleep in menopause, and the tested treatments for them come further down.

Peptides for perimenopause libido: is there one that works?

There is one, and it fits a narrow group. Bremelanotide, sold as Vyleesi and nicknamed PT-141, is an as-needed injection. Its label says how it improves desire is not known.

Vyleesi is approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder, or HSDD. HSDD means low desire that causes distress and is not explained by another condition, a relationship problem or a medicine.

Acquired means it began after a time of normal desire. Generalized means it happens in every situation. The label states it is not indicated for women after menopause, though some women in perimenopause may still fit it.

• Nausea. It affected 40 percent of women on Vyleesi in the trials, against about 1 percent on placebo.
• Blood pressure. It briefly raises blood pressure and lowers heart rate after each dose, usually settling within 12 hours. It is not for women with uncontrolled high blood pressure or known heart disease.
• Skin darkening. Darker patches on the face, gums or breasts were reported in about 1 percent of women in the trials.

Flibanserin, sold as Addyi, is a daily pill for the same condition, and it is not a peptide. Its label now covers women under 65 with acquired, generalized HSDD.

Melanotan II is a related unapproved peptide sold online for tanning and libido. It sits in the FDA's withdrawn-nominations table, and the agency cites case reports of melanoma, a serious skin cancer.

Low desire in midlife often has several causes at once, from vaginal dryness to sleep and mood. Our perimenopause libido guide walks through each cause and the treatments that match it.

Do collagen peptides do anything for menopause skin, joints or bones?

Collagen peptides are a different kind of product. They are a supplement powder made from broken-down collagen, sold over the counter rather than as a prescription drug.

The skin evidence is mixed. A 2021 meta-analysis of 19 trials, almost all in women, found better skin hydration and elasticity than placebo after about 90 days.

A larger 2025 meta-analysis of 23 trials saw the same overall gains. Its authors still concluded that no clinical evidence supports collagen for preventing or treating skin aging, because the benefit faded in the stronger trials.

For bone, a 2018 randomized trial gave 131 postmenopausal women collagen peptides or a placebo for a year. Bone density at the spine and upper thigh bone rose slightly with collagen and held flat or dipped on placebo.

One of its authors works at a collagen research institute. It is a single trial, and it did not measure fractures.

For menopausal joint pain, good collagen trials are lacking, as our perimenopause joint pain guide explains.

Copper peptide creams, labeled GHK-Cu, are skin-care cosmetics. The injectable form sits in the FDA's withdrawn-nominations table, with concerns about immune reactions and limited human data.

Our guide to the best perimenopause supplements covers the options with stronger evidence behind them.

Retatrutide, kisspeptin and other "next big thing" peptides

Retatrutide is Eli Lilly's experimental weekly shot. It acts on three gut hormone receptors, GLP-1, GIP and glucagon, and it is not FDA-approved for any use.

In July 2026, Lilly said it plans to file for FDA approval in the first quarter of 2027. It said it needed more time for manufacturing and quality data.

The FDA has warned companies selling research-labeled retatrutide to consumers. Our retatrutide vs tirzepatide comparison covers the trial results and what you can legally get today.

Kisspeptin is a natural brain hormone that helps start the release of reproductive hormones. It is studied mainly in research units for fertility and hormone problems, often given by vein.

It is not approved for any use. The FDA keeps kisspeptin-10 in Category 2 for 503A compounding, citing immune reaction and impurity concerns.

You may see kisspeptin tied to the newer hot flash pills. Veozah blocks the receptor for neurokinin B on KNDy neurons. These brain cells use kisspeptin and help run the body's temperature center. Veozah and Lynkuet are both pills, not peptides.

The other peptides the panel backed in July 2026 include MOTs-c, Epitalon and Semax. None has FDA approval, and none has a trial in menopausal women.

What actually works for menopause symptoms instead

For hot flashes and night sweats, the strongest evidence belongs to hormone therapy, often called HRT. The Menopause Society's 2022 hormone therapy position statement calls it the most effective treatment for these symptoms.

It also treats vaginal dryness and painful sex. For women under 60, or within 10 years of menopause, with no reason to avoid it, the statement finds the balance favorable.

That favorable balance covers bothersome hot flashes and women at higher risk of bone loss or fracture. HRT is not recommended for preventing heart disease.

In February 2026, the FDA approved the first HRT labels without the old boxed warning on heart disease, breast cancer and probable dementia. A boxed warning is the strongest alert on a US drug label.

A boxed warning on uterine cancer stays on estrogen-only products for women who still have a uterus.

If hormones are not right for you, The Menopause Society's 2023 nonhormone position statement recommends several options for hot flashes. They include cognitive behavioral therapy, certain antidepressants, gabapentin, fezolinetant and weight loss.

Fezolinetant is sold as Veozah. Elinzanetant, sold as Lynkuet, was approved in October 2025, after the statement came out.

Our overview of menopause treatment options compares each route, from hormone therapy to non-hormonal prescriptions.

Red flags before you buy any peptide

Most of these warning signs come straight from the FDA's advice to consumers. One of them is reason enough to stop before you pay.

• A research-only label. The product says for research purposes or not for human consumption, yet comes with dosing instructions. The FDA calls such products of unknown quality and possibly harmful.
• No prescription. There is no health questionnaire and no clinician review before checkout. The FDA lists skipping doctor screening as a red flag.
• No state-licensed pharmacy. The FDA advises buying only from state-licensed pharmacies. A seller that cannot name the pharmacy filling your order, or gives a wrong pharmacy address, fails that test.
• Semaglutide sodium or semaglutide acetate. These salt forms are different ingredients from the one in approved semaglutide. The FDA knows of no lawful basis for compounding with them. This warning is about semaglutide only.
• Claims that it is the same as Wegovy. The FDA flags any claim that a compounded drug is the same as an FDA-approved one. Compounded drugs are not FDA-approved.
• An ingredient on Category 2. Kisspeptin-10 and ibutamoren are on the FDA's Category 2 list for 503A pharmacies. Check the FDA's current list before trusting a seller.
• A warm GLP-1 delivery. The FDA advises against using an injectable GLP-1 that arrives warm or without enough refrigeration.

If you have already used a gray-market peptide and feel unwell, see a doctor promptly and bring the vial or its label.